Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA: 600332)

Market Cap	42.38B
Revenue (ttm)	76.39B
Net Income (ttm)	3.42B
Shares Out	n/a
EPS (ttm)	2.11
PE Ratio	12.38
Forward PE	n/a
Dividend	1.15 (3.95%)
Ex-Dividend Date	Oct 25, 2024

Volume	5,686,600
Open	28.80
Previous Close	28.80
Day's Range	28.42 - 28.84
52-Week Range	24.30 - 33.72
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 14, 2025

About Guangzhou Baiyunshan Pharmaceutical Holdings Company

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People’s Republic of China and internationally. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, import, and export of Western and Chinese medicines, medical ins...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1997
• Employees: 28,048
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600332

Financial Performance

In 2023, Guangzhou Baiyunshan Pharmaceutical Holdings Company's revenue was 75.52 billion, an increase of 6.68% compared to the previous year's 70.79 billion. Earnings were 4.06 billion, an increase of 2.25%.